Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
From the early sixteenth and seventeenth centuries to the present day of life, tuberculosis (TB) still is a global health threat with some new emergence of resistance. This type of emergence poses a vital challenge to control TB cases across the world. Mortality and morbidity rates are high due to this new face of TB. The newer nanotechnology-based drug-delivery approaches involving micro-metric and nano-metric carriers are much needed at this stage. These delivery systems would provide more advantages over conventional systems of treatment by producing enhanced therapeutic efficacy, uniform distribution of drug molecule to the target site, sustained and controlled release of drug molecules and lesser side effects. The main aim to develop these novel drug-delivery systems is to improve the patient compliance and reduce therapy time. This article reviews and elaborates the new concepts and drug-delivery approaches for the treatment of TB involving solid-lipid particulate drug-delivery systems (solid-lipid micro- and nanoparticles, nanostructured lipid carriers), vesicular drug-delivery systems (liposomes, niosomes and liposphere), emulsion-based drug-delivery systems (micro and nanoemulsion) and some other novel drug-delivery systems for the effective treatment of tuberculosis and role of immunomodulators as an adjuvant therapy for management of MDR-TB and XDR-TB.
a Department of Pharmaceutics , ISF College of Pharmacy , Moga , Punjab , India.
Jagdeep
J
Singh
a Department of Pharmaceutics , ISF College of Pharmacy , Moga , Punjab , India.
Tarun
T
Garg
a Department of Pharmaceutics , ISF College of Pharmacy , Moga , Punjab , India.
Goutam
G
Rath
a Department of Pharmaceutics , ISF College of Pharmacy , Moga , Punjab , India.
Amit K
AK
Goyal
D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology*; D016503:Drug Delivery Systems; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000378:metabolism; D053758:Nanoparticles / Q000737:chemistry*; D049329:Nanostructures / Q000737:chemistry*; D036103:Nanotechnology; D014376:Tuberculosis / Q000188:drug therapy* / Q000378:metabolism; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000378:metabolism
D000995:Antitubercular Agents
Carbon nanotubes; immunomodulators; nanostructured lipid carriers; quantum dots; tuberculosis